Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 17/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.39 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.39 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.39 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347914 | 0.89 | EPHX2 (0.48) | EPHX2CACNA1GEPHX1KCNH2 | |
| Trifluoroacetic Acid SCHEMBL347844 | 0.88 | EPHX2 (0.44) | EPHX2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| Trifluoroacetic Acid SCHEMBL348092 | 0.87 | PRKAA2 (0.43) | EPHX2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL346655 | 0.86 | PRKAA2 (0.46) | EPHX2EPHX1PRKAB2PRKAG1PRKAA2 | |
| Trifluoroacetic Acid SCHEMBL346884 | 0.84 | EPHX2 (0.41) | EPHX2CACNA1GKCNH2PRKAB2PRKAG1 | |
| SCHEMBL10077357 | 0.83 | KMT2A (0.41) | EPHX2EPHX1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL1839277 | 0.82 | KMT2A (0.45) | EPHX2EPHX1 | |
| Trifluoroacetic Acid SCHEMBL15310321 | 0.82 | EPHX2 (0.40) | EPHX2CACNA1GKCNH2 | |
| SCHEMBL346883 | 0.75 | ALDH1A1 (0.38) | EPHX2CACNA1GKCNH2PRKAB2PRKAG1 | |
| SCHEMBL15310413 | 0.75 | HRH3 (0.37) | CACNA1GKCNH2PRKAB2PRKAG1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759352-B2 | 1-(4-ureidobenzoyl)piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-06-24 | — | — | US | disclosed |
| EP-2318368-B1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-10-16 | — | — | EP | disclosed |
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | NPC1, ABCB11, NPC1L1 | EPHX2 1501/4885CACNA1G 2942/4885EPHX1 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.